Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,090 across all filing types
Latest filing 2017-10-16 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
2017年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "厦门艾德生物医药科技股份有限公司2017 年第三季度报告全文" which translates to "Xiamen Aide Biomedical Technology Co., Ltd. 2017 Third Quarter Report Full Text." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary for the third quarter of 2017. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly) indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2017
2017-10-16 Chinese
2017年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2017 second extraordinary general meeting (临时股东大会) of Xiamen Aide Biomedical Technology Co., Ltd. It details the legality and validity of the meeting's convening, attendance, agenda, voting procedures, and results. The document includes detailed voting results and confirms the legality of the resolutions passed. This is not a full annual or interim financial report, nor is it a simple announcement or certification. It is a legal opinion related to shareholder meeting proceedings and voting outcomes. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (7674 characters) and content support this classification with high confidence.
2017-10-12 Chinese
2017年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2017 second extraordinary general meeting of shareholders of Xiamen Aide Bio-pharmaceutical Technology Co., Ltd. It includes information about the meeting's convocation, attendance, voting results on various proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the voting outcomes and shareholder meeting procedures rather than financial results or management commentary. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is sufficient and contains substantive voting data, not just a brief announcement or a report publication notice.
2017-10-12 Chinese
2017年前三季度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the first three quarters of 2017, covering the period from January 1 to September 30, 2017. It explicitly states that the forecast is preliminary, unaudited, and that detailed actual data will be disclosed in the company's third quarter report. The document contains estimated financial performance figures but no audited or comprehensive financial statements. It is a short announcement providing preliminary earnings guidance rather than a full interim or quarterly report. Therefore, it fits the category of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. 9M 2017
2017-10-09 Chinese
中信证券股份有限公司关于公司2017年度预计日常关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion report from CITIC Securities regarding the 2017 anticipated ordinary related-party transactions of Xiamen Aide Biomedical Technology Co., Ltd. It includes descriptions of the related parties, transaction amounts, pricing principles, board and independent director opinions, and the sponsor's verification opinion. The document is not a full annual or interim financial report, nor is it an earnings release or a regulatory filing announcement. It is a specialized audit or verification report focused on related-party transactions, which fits the definition of an Audit Report / Information (AR). The document length is 3158 characters, which is relatively short but contains substantive content and detailed verification opinions, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2017
2017-09-25 Chinese
公司章程修订对照表
Governance Information Classification · 95% confidence The document is a detailed comparison table of amendments to the company's articles of association (公司章程修订对照表) for 厦门艾德生物医药科技股份有限公司. It includes specific changes to the company's charter, governance rules, shareholder rights, board and shareholder meeting procedures, and other corporate governance matters. The content is focused on governance structure and internal company rules rather than financial results, audit opinions, or capital transactions. There is no indication that this is a report of financial performance, audit, or a meeting announcement. The document is not a proxy solicitation or voting results announcement, but rather a governance document detailing the company's internal rules and their revisions. Therefore, the most appropriate classification is Governance Information (CGR). The document length and detail support a high confidence in this classification.
2017-09-25 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.